Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03359239 · ClinicalTrials.gov registry record · Phase 1
Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer
A Phase 1 study, sponsored by Matthew Galsky.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT03359239: Completed Phase 1 study, sponsored by Matthew Galsky.
NCT03359239 is a Phase 1 study that has completed, run by Matthew Galsky. The registered enrollment target is 10 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03359239, a Phase 1 study, has completed, sponsored by Matthew Galsky.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the good and bad effects of atezolizumab given in combination with a personalized cancer vaccine in patients with urothelial cancer either after surgery to remove organ where the tumor arose (for example, removal of the bladder) or for urothelial cancer that has spread to other organs.
Primary Outcome
Feasibility parameter: Number of neoantigens identified per subject
Interventions
- DRUG Atezolizumab
- DRUG Normal saline
- DRUG Poly ICLC
- BIOLOGICAL PGV001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-05-08 |
| Est. Completion | 2021-10-12 |
| Phase | Phase 1 |
What the finished NCT03359239 record still lists
NCT03359239 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 4 interventions - of which Atezolizumab is the first listed.
NCT03359239 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03359239 about?
NCT03359239 is a clinical study titled "Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer". The purpose of this study is to determine the good and bad effects of atezolizumab given in combination with a personalized cancer vaccine in patients with urothelial cancer either after surgery to remove organ where the tumor arose (for example, removal of the bladder) or for urothelial cancer that...
What is the current status of trial NCT03359239?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2019-05-08. Estimated completion is 2021-10-12.
What interventions are being tested in trial NCT03359239?
The interventions under investigation include: Atezolizumab (DRUG), Normal saline (DRUG), Poly ICLC (DRUG), PGV001 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03359239?
This trial is sponsored by Matthew Galsky, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03359239's enrollment target sits among peer trials
10 1913th of 2000 higher than 46 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI